体外成熟与体外受精的成本效果分析
该成本效果分析基于越南IVFMD医院2015年7月至2017年12月的回顾性队列数据,纳入608例接受IVM和311例接受IVF的高窦卵泡计数女性。IVM组累积活产率为39.3%,IVF组为49.8%(调整OR 0.52,95%CI 0.30-0.89);IVM组无OHSS发生,IVF组为3.5%。每对夫妇平均费用IVM为€4300,IVF为€6493,IVF每增加一例活产的ICER为€20,144。
要点
- 高AFC女性中,IVM的累积活产率低于IVF(39.3% vs 49.8%)。
- IVM组未发生OHSS,IVF组OHSS发生率为3.5%。
- IVF每增加一例活产的增量成本效果比为€20,144。
核心结论
- 在高AFC接受辅助生殖技术治疗的女性中,IVM比IVF费用更低,但累积活产率略低。
研究设计与样本
- 基于越南IVFMD医院2015年7月至2017年12月回顾性队列的成本效果分析,纳入608例IVM和311例IVF女性。
主要发现
- IVM组累积活产率为239/608(39.3%),IVF组为155/311(49.8%),调整OR为0.52(95%CI 0.30-0.89)。
- IVM组OHSS发生0例,IVF组为11/311(3.5%)。
- 每对夫妇平均费用IVM为€4300(95%CI €1371-18,798),IVF为€6493(95%CI €2204-20,136)。
- IVF每增加一例活产的ICER为€20,144(95%CI €9116-50,418)。
临床怎么用
- 对于高AFC女性,IVM可作为降低费用和避免OHSS的选择,但需权衡较低的累积活产率。
局限性
- 基于单中心回顾性队列数据,成本效果结果可能受当地医疗费用结构影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: How do costs and effects of in-vitro maturation (IVM) compare to IVF in women with a high antral follicle count (AFC)? DESIGN: This cost-effectiveness analysis (CEA) was based on data of a previous retrospective cohort study at IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam. Between July 2015 and December 2017, 608 women underwent IVM and 311 women IVF. The effectiveness measure for the CEA was cumulative live birth rate (LBR) after one completed cycle including subsequent cryo-cycles within 12 months of inclusion. Data were collected on resource use related to treatment, medication and pregnancy from the case report forms. The mean costs and effects, average cost differences and incremental cost-effectiveness ratios (ICER) were calculated using non-parametric bootstrap resampling to assess the effect of uncertainty in the estimates. RESULTS: Cumulative LBR after one completed cycle were 239/608 (39.3%) in the IVM group versus 155/311 (49.8%) in the IVF group (adjusted odds ratio 0.52, 95% confidence interval [CI] 0.30-0.89). Ovarian hyperstimulation syndrome (OHSS) did not occur in the IVM group versus 11/311 (3.5%) in the IVF group. The mean costs per couple were €4300 (95% CI €1371-18,798) for IVM and €6493 (95% CI €2204-20,136) for IVF. The ICER per additional live birth with IVF was €20,144 (95% CI €9116-50,418). Results were robust over a wide range of assumptions. CONCLUSIONS: IVM is less expensive than IVF in women with a high AFC undergoing treatment with assisted reproductive technology, while leading to a slightly lower effectiveness in terms of cumulative LBR.
引用
- Braam SC, Ho VNA, Pham TD, et al. In-vitro maturation versus IVF: a cost-effectiveness analysis. Reprod Biomed Online. 2020. PMID: 33132059. doi:10.1016/j.rbmo.2020.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。